TGFα expression in myeloid malignancies

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background Transforming growth factor α (TGFα) is a peptide growth factor known to be expressed in normal haemopoiesis. It is also expressed in a range of epithelial neoplasms but has not been assessed in haemopoietic malignancies. We have performed an immunohistochemical evaluation of TGFα in acute and chronic myeloid malignancies. Methods TGFα expression was semiquantitatively assessed in 69 normal bone marrow trephines and 157 cases of myeloid malignancy using an immunohistochemical approach. Results Blast cells of myeloid origin in acute myeloid leukaemia (AML), myelodysplasia and accelerated and blast phases of chronic myeloid leukaemia (CML) were TGFα positive. In acute promyelocytic leukaemia the neoplastic cells had significantly weaker TGFα expression than seen in other forms of AML. The blast cells in CML-accelerated and blast phases were positive with similar expression to AML. Conclusions TGFα is expressed in neoplastic myeloblasts and could, therefore, be used as blast cell biomarker in diagnostic haematopathology. In addition, TGFα immunohistochemistry may be of use in identifying a therapeutic target.
Original languageEnglish
Pages (from-to)543-546
JournalJournal of Clinical Pathology
Volume69
Issue number6
DOIs
Publication statusPublished - 2016

Fingerprint

Transforming Growth Factors
Neoplasms
Acute Myeloid Leukemia
Blast Crisis
Leukemia, Myeloid, Accelerated Phase
Granulocyte Precursor Cells
Acute Promyelocytic Leukemia
Glandular and Epithelial Neoplasms
Myeloid Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intercellular Signaling Peptides and Proteins
Biomarkers
Bone Marrow
Immunohistochemistry
Peptides

Cite this

@article{b7a34ee410a34393b2c965cf242eb74f,
title = "TGFα expression in myeloid malignancies",
abstract = "Background Transforming growth factor α (TGFα) is a peptide growth factor known to be expressed in normal haemopoiesis. It is also expressed in a range of epithelial neoplasms but has not been assessed in haemopoietic malignancies. We have performed an immunohistochemical evaluation of TGFα in acute and chronic myeloid malignancies. Methods TGFα expression was semiquantitatively assessed in 69 normal bone marrow trephines and 157 cases of myeloid malignancy using an immunohistochemical approach. Results Blast cells of myeloid origin in acute myeloid leukaemia (AML), myelodysplasia and accelerated and blast phases of chronic myeloid leukaemia (CML) were TGFα positive. In acute promyelocytic leukaemia the neoplastic cells had significantly weaker TGFα expression than seen in other forms of AML. The blast cells in CML-accelerated and blast phases were positive with similar expression to AML. Conclusions TGFα is expressed in neoplastic myeloblasts and could, therefore, be used as blast cell biomarker in diagnostic haematopathology. In addition, TGFα immunohistochemistry may be of use in identifying a therapeutic target.",
author = "Simon Kavanagh and Bob Mirzai and Kathy Fuller and Wendy Erber",
year = "2016",
doi = "10.1136/jclinpath-2015-203526",
language = "English",
volume = "69",
pages = "543--546",
journal = "Journal of Clinical Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "6",

}

TGFα expression in myeloid malignancies. / Kavanagh, Simon; Mirzai, Bob; Fuller, Kathy; Erber, Wendy.

In: Journal of Clinical Pathology, Vol. 69, No. 6, 2016, p. 543-546.

Research output: Contribution to journalArticle

TY - JOUR

T1 - TGFα expression in myeloid malignancies

AU - Kavanagh, Simon

AU - Mirzai, Bob

AU - Fuller, Kathy

AU - Erber, Wendy

PY - 2016

Y1 - 2016

N2 - Background Transforming growth factor α (TGFα) is a peptide growth factor known to be expressed in normal haemopoiesis. It is also expressed in a range of epithelial neoplasms but has not been assessed in haemopoietic malignancies. We have performed an immunohistochemical evaluation of TGFα in acute and chronic myeloid malignancies. Methods TGFα expression was semiquantitatively assessed in 69 normal bone marrow trephines and 157 cases of myeloid malignancy using an immunohistochemical approach. Results Blast cells of myeloid origin in acute myeloid leukaemia (AML), myelodysplasia and accelerated and blast phases of chronic myeloid leukaemia (CML) were TGFα positive. In acute promyelocytic leukaemia the neoplastic cells had significantly weaker TGFα expression than seen in other forms of AML. The blast cells in CML-accelerated and blast phases were positive with similar expression to AML. Conclusions TGFα is expressed in neoplastic myeloblasts and could, therefore, be used as blast cell biomarker in diagnostic haematopathology. In addition, TGFα immunohistochemistry may be of use in identifying a therapeutic target.

AB - Background Transforming growth factor α (TGFα) is a peptide growth factor known to be expressed in normal haemopoiesis. It is also expressed in a range of epithelial neoplasms but has not been assessed in haemopoietic malignancies. We have performed an immunohistochemical evaluation of TGFα in acute and chronic myeloid malignancies. Methods TGFα expression was semiquantitatively assessed in 69 normal bone marrow trephines and 157 cases of myeloid malignancy using an immunohistochemical approach. Results Blast cells of myeloid origin in acute myeloid leukaemia (AML), myelodysplasia and accelerated and blast phases of chronic myeloid leukaemia (CML) were TGFα positive. In acute promyelocytic leukaemia the neoplastic cells had significantly weaker TGFα expression than seen in other forms of AML. The blast cells in CML-accelerated and blast phases were positive with similar expression to AML. Conclusions TGFα is expressed in neoplastic myeloblasts and could, therefore, be used as blast cell biomarker in diagnostic haematopathology. In addition, TGFα immunohistochemistry may be of use in identifying a therapeutic target.

U2 - 10.1136/jclinpath-2015-203526

DO - 10.1136/jclinpath-2015-203526

M3 - Article

VL - 69

SP - 543

EP - 546

JO - Journal of Clinical Pathology

JF - Journal of Clinical Pathology

SN - 0021-9746

IS - 6

ER -